Work

The good, the bad, the ugly: Optimal left ventricular assist device duration in bridge to transplantation

Year: 2021

Type: article

Abstract: Left ventricular assist devices (LVADs) are an important treatment option for patients with end-stage heart failure refractory to optimal medical management. Compared with medical therapy, LVADs improve quality of life and survival.1,2 Over the past decade, approximately 50% of patients received an LVAD as destination therapy (DT), whereas close to 25% received a device as a either a bridge to transplant (BTT) or bridge to candidacy (BTC).3 In 2018, the US heart allocation system was modified in such a way that priority of patients who are stable with an LVAD was less emphasized.

Source: JTCVS Open

DOI: 10.1016/j.xjon.2021.10.013

Authors: Matthew L. Goodwin, Hiroshi Kagawa, Craig H. Selzman

Institution: University of Utah

Language: English

Topic: Mechanical Circulatory Support Devices

Subfield: Biomedical Engineering

Field: Engineering

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,100